An Update on the Physiology of Atrial Natriuretic Factor

NICK C. TRIPPODO

SUMMARY The atrial natriuretic factor (ANF) has pharmacological actions resulting in lower atrial and arterial pressures. Atrial distention stimulates ANF release, suggesting that ANF is an effector limb of a feedback loop for controlling cardiac filling pressure. To test this hypothesis it will be necessary to determine whether physiological atrial distention releases ANF in sufficient amounts to exert biological actions. Immunoblockade of endogenous ANF and attenuation of ANF release by atrial ablation inhibited volume-induced natriuresis in rats. Infusion of ANF in rats at doses mimicking those observed during experimental volume expansion produced a natriuresis sufficient to partly account for the volume-induced response. Infusion of ANF at doses expected to change plasma ANF levels minimally decreased arterial pressure in hypertensive rats over 7 days. In dogs, some studies suggest that increased plasma ANF levels following experimental changes in atrial pressure were not sufficient to exert acute cardiovascular or renal actions, whereas others support such a notion and indicate that ANF inhibited barostimulated renal renin release. This last action could alter arterial pressure in the long term by allowing sodium equilibrium at lower renal arterial pressure. Infusion of ANF in humans that produced plasma levels in the upper physiological range caused increased sodium excretion and decreased plasma renin activity. Although data are exiguous, justifying neither acceptance nor rejection of the hypothesis that ANF functions physiologically to regulate body fluid volume and arterial pressure, the current evidence slightly favors acceptance.

(Hypertension 10 [Suppl I]: I-122-I-127, 1987)

KEY WORDS • plasma atrial natriuretic factor concentration • cardiovascular and renal actions • prolonged infusion

This discussion reviews recent data relating to the possible physiological relevance of the atrial natriuretic factor (ANF) as a regulator of urinary sodium excretion and arterial blood pressure.

Release of ANF

It is generally accepted that pro-ANF, ANF (1-126), is stored in the atrial granules, whereas the smaller more active peptide, ANF (99-126) predominates in the circulation. Human atria may also contain a dimer of ANF (99-126), of which a small amount may be found in the plasma, although this is not a consistent finding. It appears that immediately before, during, or promptly after release, pro-ANF is cleaved by a processing enzyme to yield the active carboxy terminus, ANF (99-126) and the amino terminal portion ANF (1-98). Whether the latter peptide possesses biological activity is unknown, but it is released into the circulation together with the active hormone.

A review of the literature suggests that physiological perturbations associated with rises in atrial pressure (exercise, immersion, head-down tilt, etc.) can result in twofold to threefold increases in plasma immunoreactive ANF; whereas in pathophysiological conditions associated with elevated cardiac filling pressure (congestive heart failure, chronic renal failure) or cardiac arrhythmias (paroxysmal atrial tachycardia) plasma ANF may be 20 times greater than normal. Atrial distention is certainly at least one factor that influences the secretion of ANF and appears to operate by an intrinsic stretch-secretion coupling mechanism, since isolated atria release ANF in direct proportion to mechanical load. This mechanism alone could account for the well-established finding of increased circulating ANF associated with increased cardiac filling pres-
sure. Whether ANF release is modulated by neurotransmitters, circulating factors, or heart rate per se is less certain.

Physiological Effects of ANF

To evaluate the importance of ANF as a hormone it is necessary to determine if this peptide exerts biological actions at circulating levels encountered during physiological conditions or in pathophysiological situations. The present state of knowledge precludes categorical conclusions, however. First, there is little information about the effects of blockade of endogenous ANF. Second, as with other peptide hormones, some physiological actions may require several days to develop fully, and thus may only be apparent if ANF is administered for a prolonged time; information of this nature is sparse. Finally, although numerous reports have appeared concerning plasma concentration of immunoreactive ANF in humans and experimental animals, only a few studies documented the plasma levels of immunoreactive ANF after exogenous administration to be within the range of those measured during various physiological or pathophysiological states.

It is important for two reasons that such comparisons be done in each laboratory where these studies are conducted. One reason is that the loss of peptide by adsorption to the delivery system can markedly decrease the actual dose from that calculated. Because the amount of loss can vary among laboratories, this precludes extrapolation of the plasma concentration from the calculated dose. Another reason is the variation in the radioimmunoassay of ANF among laboratories. To obviate interference from plasma proteins, most workers now measure ANF immunoreactivity in plasma extracts rather than by direct assays. Using plasma extract, a majority of studies show mean values for basal plasma ANF of healthy volunteers ranging as low as 2 to 12 pg/ml or as high as 27 to 152 pg/ml for basal levels of plasma ANF in healthy subjects. Differences in procedures for collecting and storing samples, extraction recoveries, specificities of antibodies, and purities of standards probably account for these disparities.

Thus, in this discussion, assessment as to whether or not a reported plasma ANF level after infusion of exogenous ANF falls within the physiological range is based only on comparison to the range of plasma values actually measured in the same laboratory where the infusion was carried out and using the same assay procedures as were used to measure the plasma levels after infusion. Also, unless otherwise specified, only values obtained from extracted plasma are discussed.

Rats

With regard to blockade of endogenous ANF, in two studies antibodies against ANF were administered intravenously to Inactin-anesthetized rats. Injection of an anti-ANF antiserum caused a marked decrease in urine volume output and urinary sodium excretion last-
animals. This suggests that in dogs the release of ANF contained in the atrial appendages is not necessary for the normal renal response to this perturbation. It is possible, however, that the 10- to 14-day surgical recovery period was sufficient time for the granules in the remaining atrial tissue to proliferate in compensation for those lost, and that an increase in plasma ANF occurred despite the removal of the atrial appendages.

In another study, right atrial pressure was increased in conscious dogs by inflating an in-dwelling balloon above the atrioventricular valve. Plasma ANF concentration increased from 73 to 189 pg/ml, yet the sodium excretion rate did not change. This increment in plasma ANF concentration was similar to that reported by others during graded saline volume expansion in anesthetized dogs (70–172 pg/ml). When left atrial pressure was increased in conscious cardiac-depilated dogs by the same type of maneuver, plasma ANF increased from 62 to 260 pg/ml, again with no change in urine volume output or urinary sodium excretion. These results suggest that in dogs the increase in plasma ANF concentration after atrial distension is not sufficient to exert an acute natriuretic effect.

Preliminary findings from a different laboratory also suggested that the increased plasma ANF levels observed during atrial pacing and increased atrial pressure in dogs was not sufficient to account for the natriuresis that occurred during these maneuvers. In contrast, others have found that short-term (60 minutes) infusion of ANF in conscious dogs, at doses that mimicked changes in endogenous ANF observed during increased atrial pressure or deoxycorticosterone acetate (DOCA) treatment, resulted in significant effects on the cardiovascular and renal systems. For instance, increasing right or left atrial pressure by 3 to 5 mm Hg caused plasma ANF concentration to increase from 50 to 55 pg/ml to over 200 pg/ml. Administration of DOCA in dogs caused plasma ANF to increase from 42 to 99 pg/ml by Day 8 of treatment. During infusion of ANF at 10 ng·min⁻¹·kg⁻¹, plasma ANF increased to 134 pg/ml as compared with 55 pg/ml for the time control, while urinary sodium excretion doubled, mean arterial pressure decreased by 9 mm Hg, and heart rate did not change. These results suggest that physiologically feasible plasma levels of ANF could have an influence on renal sodium excretion and arterial blood pressure in dogs. Currently, there is no clear explanation for the discrepancy between studies. Thus, although agreement exists among laboratories that plasma ANF concentration in dogs increases in response to elevated atrial pressure and intravascular volume expansion, the results with respect to whether these circulating levels exert physiological effects are at odds.

**Humans**

Continuous infusion of ANF into healthy subjects at approximately 50 ng·min⁻¹·kg⁻¹ for 30 to 60 minutes increased plasma ANF levels to the upper range observed in pathophysiological states. In healthy subjects on a high salt diet, this plasma ANF level follow-

ing infusion of the peptide was associated with threefold increase in urinary sodium excretion, a decrease in plasma aldosterone concentration, and no change in plasma cortisol concentration, plasma renin activity, or arterial blood pressure. Conceivably, in some circumstances ANF could cause reciprocal changes in cardiac output and total peripheral resistance, while arterial blood pressure changes very little. Indeed, when ANF was administered as a 125-kg bolus followed by 25 ng·min⁻¹·kg⁻¹, stroke volume was significantly decreased 30 minutes after the start of infusion, but arterial blood pressure was not different from control level. Plasma ANF concentration increased from 54 to 457 pg/ml and was stated to be within the physiological range, although data in that regard were not reported.

Exogenously administered ANF may also have biological actions in humans at even lower blood levels. A 6-hour infusion of ANF at 6 ng·min⁻¹·kg⁻¹ in male volunteers produced a transient twofold increase in urinary sodium excretion and a 2.6-fold increase in urine flow. Although not documented, it is likely that plasma ANF concentration increased to within the high physiological or pathophysiological range after this low dose.

In a similar study, ANF was infused into water-loaded, normal subjects at 3.7 ng·min⁻¹·kg⁻¹ for 3 hours, achieving plasma ANF concentrations within the upper part of the physiological range for that laboratory. This infusion increased sodium excretion 60% and decreased plasma renin activity 25%, but had no effects on plasma aldosterone concentration, arterial pressure, or heart rate. Thus the available data in humans suggest that ANF has renal, endocrine, and cardiovascular actions at plasma levels observed in some circulatory disorders, and that at physiological levels it has a natriuretic effect and suppresses renin secretion.

**Prolonged Infusion**

Rat ANF (101–126) was infused by osmotic pumps into rats with various forms of hypertension at approximately 5 ng·min⁻¹·kg⁻¹. Systolic blood pressure, measured indirectly, decreased gradually over 7 days in spontaneously hypertensive rats (SHR) and in rats with one-kidney, one clip or two-kidney, one clip26 renal hypertension. Compared with noninfused rats, urinary sodium excretion was increased,26 not different,25 or decreased,27 perhaps depending on the type of hypertension. No changes in systolic blood pressure or natriuresis were observed in normotensive rats infused with the same dose of ANF.

In a similar study, human ANF (99–126) was infused at approximately 7 ng·min⁻¹·kg⁻¹ into SHR and normotensive rats maintained on high or low sodium intake. Systolic blood pressure decreased within 24 hours after implanting the peptide-filled pump in all four groups and remained depressed throughout the 7-day infusion. Urinary sodium excretion gradually increased only in the SHR maintained on the high sodium diet, supporting previous findings that the de-
pressor effect of prolonged infused ANF was not initiated by sodium depletion. These findings, from two different laboratories, that prolonged infusion of ANF at doses not expected to increase plasma ANF concentration by a detectable amount, as measured by current assay methods, lowered arterial blood pressure in hypertensive and, in one study, normotensive rats are intriguing. These studies should be extended to include measurements of arterial blood pressure by direct methods, other hemodynamic variables, and plasma ANF concentration.

Similar novel results occurred in patients with severe congestive heart failure who received ANF infusion at 8 ng·min⁻¹·kg⁻¹ for 2 hours. Glomerular filtration rate and renal plasma flow increased markedly despite the low dose of ANF, and the fact that it was administered to patients with a disorder known to be associated with elevated levels of circulating ANF. Clearly, more work is needed to verify these early observations on the effects of low level infusions of ANF and to examine their potential importance.

In other studies, the relative potencies of rat ANF (103–126), ANF (103–125), and ANF (103–123) were compared for smooth muscle relaxing activity, acute hypotensive activity, and long-term hypotensive action (7 days) in SHR. Although differences in potencies were observed for the first two biological actions, the three peptides had equal potencies for the long-term blood pressure–lowering effect when infused at 0.4 nmol·h⁻¹·kg⁻¹ (approximately 15 ng·min⁻¹·kg⁻¹). It is reasonable to assume, although it was not documented, that the circulating level of ANF achieved by this dose did not exceed the physiological range. These findings suggest that the mechanisms by which ANF alters the long-term control of arterial pressure may be different from those operating over the short term or in relaxing aortic smooth muscle.

Higher doses of ANF (40–100 ng·min⁻¹·kg⁻¹) infused for 3 to 7 days were hypotensive but not natriuretic in the following rat models of hypertension: two-kidney, one clip hypertension decreased plasma renin activity 11-fold increase in plasma ANF concentration, mean arterial pressure decreased significantly over the 5-day infusion. No long-term effects were observed on glomerular filtration rate, urinary sodium excretion, plasma renin activity, or plasma aldosterone concentration. The lack of increase in plasma renin activity despite the decrease in arterial pressure and presumably renal perfusion pressure suggested a sustained inhibitory effect of ANF on barostimulated renin release. This notion is supported by the observation that long-term infusion of ANF into rats with two-kidney, one clip hypertension decreased plasma renin activity to normal levels.

A powerful effect of ANF to inhibit barostimulated renin secretion was also demonstrated in short-term studies in dogs. Infusion at only 5 ng·min⁻¹·kg⁻¹, which increased plasma ANF concentration 70%, abolished the effectiveness of decreased renal perfusion pressure to increase plasma renin activity. These studies demonstrate that physiological plasma levels of ANF have the potential to modulate the activity of an important pressure–fluid volume homeostatic control system.

Thus prolonged infusion of ANF into hypertensive rats and normotensive dogs at doses ranging from low physiological to high pathological or pharmacological resulted in sustained decreases in arterial blood pressure without consistent changes in urinary sodium excretion. This suggests that ANF infusion altered the long-term renal pressure–natriuresis mechanism such that sodium equilibrium was maintained at a lower renal perfusion pressure. ANF could effect this new equilibrium by acting directly in the kidneys or by modulating other systems that impinge on cardiovascular and renal functions, such as the renin–angiotensin–aldosterone system and the sympathetic nervous system. This has important therapeutic implications if ANF analogues are to be used for treating patients with hypertension or heart failure. Although it is not established that ANF has this capacity under physiological conditions, evidence suggests that exogenously administered ANF has an antihypertensive effect at fairly low plasma concentrations. This observation requires verification by direct measurement of arterial pressure, plasma ANF concentration, and other hemodynamic variables.

**Perspective**

The available data justify neither acceptance nor rejection of the hypothesis that ANFs function under physiological conditions to regulate urinary sodium excretion and arterial blood pressure. Although some
of the data are conflicting, the greatest obstacle in assessing the possible physiological importance of ANF is the paucity of crucial information. After synthetic ANF became available, a surge of in vivo studies were conducted using pharmacological doses. These provided important information regarding possible therapeutic effects of ANF and verified the biological actions observed earlier with crude atrial extract. Indeed, more studies of this nature are warranted so that mechanisms of action can be determined.

A second wave of studies designed to examine the actions of ANF at physiological levels is just under way. Critical interpretations of these data should include some of the following considerations. First, ANF administered at physiological levels might have only subtle, nondetectable effects in the short term, but if administered over a period of days or weeks the effects could be amplified by its concurrent actions on other regulating systems, such as the renin-angiotensin-aldosterone and autonomic nervous systems.

Second, the importance of ANF as a hormone may differ among species. For instance, a reflex mechanism linking atrial stretch and renal function appears to be prominent in dogs but less important in nonhuman primates. Perhaps the humoral component of this atrial stretch-natriuresis response is more important than the neural element in some species.

Third, administration of ANF at physiological doses may cause important cardiovascular and body fluid volume alterations that could go unnoticed if certain variables are not measured. For instance, ANF infusion in humans led to a decrease in stroke volume without causing a change in arterial blood pressure, presumably partly because of reflex vasoconstriction. At pharmacological doses, ANF decreased blood volume and central venous pressure in anephric rats, presumably because of fluid migration into the interstitium and perhaps because of increased resistance to venous return. If only arterial blood pressure is measured, possible cardiac output and venous return effects of ANF may not be observed, and if only urinary sodium excretion is measured, possible blood volume changes may not be observed.

Finally, the importance of the renal pressure-natriuresis mechanism in maintaining sodium and water balance should be taken into account. According to this concept, arterial pressure has a dominant long-term influence on sodium and water excretion that could override the natriuretic effects of ANF and other natriuretic factors. This mechanism could be the fundamental force causing sodium retention in congestive heart failure, despite high circulating levels of ANF. However, the presumed dominance of the renal pressure-natriuresis mechanism does not preclude an important role for ANF in sodium homeostasis and arterial blood pressure regulation. Just as angiotensin II displaces this relationship to higher pressures, ANF could shift it in the opposite direction. Further studies are needed to compare the potencies of these two counteractive peptides in altering the long-term relationship between renal perfusion pressure and natriuresis.

It is reasonable to expect that, given the widespread interest in this putative new hormone, the physiological studies essential for assessing its possible contribution to body fluid regulation and arterial blood pressure control will be forthcoming in the near future. Furthermore, studies of this nature will surely be spurred if and when an ANF antagonist becomes available. As of this writing, a few studies suggest that ANF has cardiovascular, renal, and hormonal actions at physiologically feasible blood levels in rats, dogs, and humans, although the evidence in dogs is controversial.

References


An update on the physiology of atrial natriuretic factor.
N C Trippodo

Hypertension. 1987;10:1122
doi: 10.1161/01.HYP.10.5_Pt_2.1122

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1987 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/10/5_Pt_2/1122

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org/subscriptions/